Canada Lung Cancer Therapeutics Market to be Dominated by Non-small Cell Lung Cancer Type through 2028
The growing
demand for novel and safer therapies is expected to drive the growth of Canada
Lung Cancer Therapeutics Market in the forecast period, 2024-2028.
According
to TechSci Research report, “Canada Lung
Cancer Therapeutics Market - By Region, Competition Forecast and Opportunities, 2018-2028,” the
Canada Lung Cancer Therapeutics Market is anticipated to grow at an impressive
rate in the forecast period 2024-2028. This can be attributed to the increasing
funding in the field of research and development of new drugs, increasing
pollution due to rapid industrialization, and a rise in the number of smokers
across the country. Similarly, rising research and development expenses have
resulted in the development of advanced targeted therapeutics to treat lung
cancer, which is one of the major factors propelling the growth of the Canada
Lung Cancer Therapeutics Market over the years. Additionally, rising healthcare
expenditure along with the growing awareness regarding the availability of
advanced gene therapies that can cure traditionally non-curable diseases will
further drive the growth of the Canada Lung Cancer Therapeutics market during
the forecast period.
However, lung cancer continues to be a major public
health concern in Canada, causing significant morbidity and mortality. The high
disease burden places a strain on healthcare resources, including diagnostics,
treatment facilities, and healthcare professionals, which may hamper the growth
of the Canada Lung Cancer Therapeutics market during the forecast period.
Similarly, due to the lack of specific symptoms in the early stages and limited
routine screening programs, many cases are detected at advanced stages when
treatment options are more limited, which may also hamper the growth of the
market during the forecast period. Also, while targeted therapies have
revolutionized the treatment landscape for specific lung cancer subtypes, such
as EGFR-mutated or ALK-positive lung cancer, there are still subsets of
patients with limited treatment options, which can further restrict the growth
of the Canada Lung Cancer Therapeutics Market.
Browse
over XX market data Figures spread through 70
Pages and an in-depth TOC on "Canada Lung Cancer Therapeutics Market.”
Canada Lung Cancer Therapeutics market can be segmented
by Cancer Cell Type, Treatment, End User, Region and Competitive Landscape.
Based
on the classification of Cancer Cell Type, the market can be categorized into
Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). The
non-small cell lung cancer segment exhibited dominance in the Canada Lung
Cancer Therapeutics market in 2022 and is projected to maintain its leading
position throughout the forecast period. This can be attributed to the growing
prevalence of non-small cell lung cancer among the population and the
increasing awareness among patients about the disease, as well as the
availability of advanced therapeutics for treatment.
Based
on the End User, the Canada Lung Cancer Therapeutics market can be segmented
into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. The
Hospital Pharmacies segment is expected to dominate the Canada Lung Cancer
Therapeutics market during the forecast period. This is primarily due to the
higher volume of patient admissions in hospitals for cancer treatment and
diagnosis, and the preference of consumers to purchase drugs from hospital
pharmacies in the country.
Major
companies operating in Canada Lung Cancer Therapeutics market are:
- AstraZeneca
Canada Inc
- Boehringer
Ingelheim Canada Ltd
- Bristol-Myers
Squibb Canada Inc
- Eli
Lilly Canada Inc
- Hoffmann-La
Roche Ltd
- Merck
& Co Inc
- Pfizer
Canada Inc
- Allergan
Inc/Canada
- Johnson
& Johnson Inc/Canada
Download Free Sample Report
Customers can also request for 10% free customization
on this report.
“Canada
Lung Cancer Therapeutics is expected to grow during the forecast period due to
the rising prevalence of lung cancer and the growing adoption of advanced
diagnosis and therapeutics for its treatment. Similarly, the presence of
several top biopharmaceutical companies in the country is expected to drive the
growth of the market. Furthermore, funds and regulatory support from government
bodies and agencies will further propel the growth of the Canada Lung Cancer
Therapeutics market. Additionally, the increased penetration of health
insurance in Canada has resulted in improved access to advanced and costly
therapeutics, which is a major factor influencing the market's growth.
Moreover, the presence of a strong and developed healthcare infrastructure,
along with improved access to advanced healthcare facilities, is expected to
create lucrative growth opportunities for the Canada Lung Cancer Therapeutics
market,” said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based global management consulting firm.
“Canada Lung Cancer Therapeutics Market By Cancer Cell
Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), By
Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy,
Other Treatments), By End User (Hospital Pharmacies, Retail Pharmacies, Online
Pharmacies, Others) and By Region, Competition Forecast and Opportunities,
2018-2028,” has
evaluated the future growth potential of Canada Lung Cancer Therapeutics Market
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Canada Lung Cancer Therapeutics Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com